Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label, Single-Arm Study of JS212 in Combination With JS111 as First-Line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT07714304 is registered in ClinicalTrials.gov with Huan Zhou as lead sponsor.

NCT NCT07714304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07714304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label, Single-Arm Study of JS212 in Combination With JS111 as First-Line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Huan Zhou
Phase
Not applicable
Overall status
Not yet recruiting
Start date
July 13, 2026
Completion date
July 23, 2029
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc harboring egfr mutations